Concert Pharma (CNCE) Misses Q3 EPS by 11c

Concert Pharma (NASDAQ: CNCE) reported Q3 EPS of ($0.74), $0.11 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $11 thousand versus the consensus estimate of $10 thousand.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c